TY - JOUR
T1 - Circulating blood circular RNA in Parkinson’s Disease; from involvement in pathology to diagnostic tools in at-risk individuals
AU - Beric, Aleksandra
AU - Sun, Yichen
AU - Sanchez, Santiago
AU - Martin, Charissa
AU - Powell, Tyler
AU - Kumar, Ravindra
AU - Pardo, Jose Adrian
AU - Darekar, Gauri
AU - Sanford, Jessie
AU - Dikec, Devin
AU - Phillips, Bridget
AU - Botia, Juan A.
AU - Cruchaga, Carlos
AU - Ibanez, Laura
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - To identify circRNAs associated with Parkinson’s disease (PD) we leveraged two of the largest publicly available studies with longitudinal clinical and blood transcriptomic data. We performed a cross-sectional study utilizing the last visit of each participant (N = 1848), and a longitudinal analysis that included 1166 participants with at least two time points. We identified 192 differentially expressed circRNAs, with effects that were sustained during disease, in mutation carriers, and diverse ancestry. The 192 circRNAs were leveraged to distinguish between PD and healthy participants with a ROC AUC of 0.797. Further, 71 circRNAs were sufficient to distinguish between genetic PD (AUC71 = 0.954) and, at-risk participants (AUC71 = 0.929) and healthy controls, supporting that circRNAs have the potential to aid the diagnosis of PD. Finally, we identified five circRNAs highly correlated with symptom severity. Overall, we demonstrated that circRNAs play an important role in PD and can be clinically relevant to improve diagnostic and monitoring.
AB - To identify circRNAs associated with Parkinson’s disease (PD) we leveraged two of the largest publicly available studies with longitudinal clinical and blood transcriptomic data. We performed a cross-sectional study utilizing the last visit of each participant (N = 1848), and a longitudinal analysis that included 1166 participants with at least two time points. We identified 192 differentially expressed circRNAs, with effects that were sustained during disease, in mutation carriers, and diverse ancestry. The 192 circRNAs were leveraged to distinguish between PD and healthy participants with a ROC AUC of 0.797. Further, 71 circRNAs were sufficient to distinguish between genetic PD (AUC71 = 0.954) and, at-risk participants (AUC71 = 0.929) and healthy controls, supporting that circRNAs have the potential to aid the diagnosis of PD. Finally, we identified five circRNAs highly correlated with symptom severity. Overall, we demonstrated that circRNAs play an important role in PD and can be clinically relevant to improve diagnostic and monitoring.
UR - http://www.scopus.com/inward/record.url?scp=85209597317&partnerID=8YFLogxK
U2 - 10.1038/s41531-024-00839-3
DO - 10.1038/s41531-024-00839-3
M3 - Article
C2 - 39557914
AN - SCOPUS:85209597317
SN - 2373-8057
VL - 10
JO - npj Parkinson's Disease
JF - npj Parkinson's Disease
IS - 1
M1 - 222
ER -